All In Biotech

Drug Trial Radar · NCT06813911

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C and Lp(a)

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 246 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

246

Actual

Start

Apr 30, 2025

Primary completion

Feb 3, 2028

Study completion Feb 29, 2028

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study CTQJ230A12304, is to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo in participants with ASCVD who have elevated lipoprotein(a) (Lp(a)), and who are on background inclisiran treatment for elevated low-density lipoprotein cholesterol (LDL-C). Study has been terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint

Conditions

  • Atherosclerotic Cardiovascular Disease (ASCVD)

Interventions

  • PelacarsenDrug

    Pelacarsen will be provided as solution for injection in prefilled syringe 80 mg for subcutaneous injection.

  • PlaceboDrug

    Placebo will be provided as solution for injection in prefilled syringe for subcutaneous injection.

  • InclisiranDrug

    All participants will be administered two loading doses of inclisiran as background treatment at Run-in 1 and Run-in 2, separated by 3 months, according to the approved label. After that inclisiran will be administered every 6 months, i.e., Month 5 and Month 11.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in log transformed lipoprotein A (Lp(a)) concentrationTime frame: Baseline, 6 Months

Locations

94 sites in 11 countries. Site status is shown where the registry gives one.

  • Parkway Medical Center

    Birmingham, Alabama

  • Clinical Research Inst of Arizona

    Sun City West, Arizona

  • National Heart Institute

    Beverly Hills, California

  • Interv Cardiology Med Grp

    West Hills, California

  • Excel Medical Clinical Trials LLC

    Boca Raton, Florida

  • Jacksonville Center for Clinical

    Jacksonville, Florida

  • K2 Medical Research LLC

    Maitland, Florida

  • University of Miami Hospital

    Miami, Florida

  • Baptist Health South

    Miami, Florida

  • Inpatient Research Clinical LLC

    Miami Lakes, Florida

  • FXM Clin Res Miramar LLC

    Miramar, Florida

  • Ocala Cardiovascular Research

    Ocala, Florida

  • SEC Clinical Research

    Pensacola, Florida

  • Peace River Cardiovascular Center

    Port Charlotte, Florida

  • University Of South Florida

    Tampa, Florida

  • FC Site Partners Miami

    Winter Park, Florida

  • Advocate Lutheran General Childrens Hospital

    Park Ridge, Illinois

  • American Health Network Research Dept

    Muncie, Indiana

  • Cardiovascular Associates Research

    Covington, Louisiana

  • Omega Clinical Research

    Metairie, Louisiana

  • Flourish Research Bowie

    Bowie, Maryland

  • Anderson Medical Research

    Ft. Washington, Maryland

  • Henry Ford Hospital

    Detroit, Michigan

  • Aa Mrc Llc

    Flint, Michigan

  • MyMichigan Medical Center Midland

    Midland, Michigan

  • AB Clinical Trials

    Las Vegas, Nevada

  • Overlook Medical Center

    Summit, New Jersey

  • Wake Forest University Baptist Medical Center

    Winston-Salem, North Carolina

  • The Corvallis Clinic P C

    Corvallis, Oregon

  • Novartis Investigative Site

    Tullahoma, Tennessee

  • PharmaTex Research LLC

    Amarillo, Texas

  • Kelsey Seybold Research Foundation

    Houston, Texas

  • Northwest Houston Clinical Research PLLC

    Tomball, Texas

  • Intermountain Medical Center

    Murray, Utah

  • Virginia Heart

    Falls Church, Virginia

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Shanghai, China

  • Novartis Investigative Site

    Yinchuan, Ningxia, China

  • Novartis Investigative Site

    Jining, Shandong, China

  • Novartis Investigative Site

    Xian, Shanxi, China

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.